Bausch Health ehemals VALEANT PHARMA Allergan-Übernahme beflügelt (Seite 252)
eröffnet am 30.04.14 17:10:46 von
neuester Beitrag 10.04.24 21:16:45 von
neuester Beitrag 10.04.24 21:16:45 von
Beiträge: 4.274
ID: 1.193.944
ID: 1.193.944
Aufrufe heute: 9
Gesamt: 390.072
Gesamt: 390.072
Aktive User: 0
ISIN: CA0717341071 · WKN: A2JQ1X · Symbol: BVF
6,3420
EUR
-2,60 %
-0,1690 EUR
Letzter Kurs 17.05.24 Tradegate
Neuigkeiten
17.05.24 · Accesswire  |
15.05.24 · Accesswire |
14.05.24 · Accesswire |
09.05.24 · Accesswire |
02.05.24 · Accesswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,8000 | +45,45 | |
| 1,0000 | +42,86 | |
| 3,0000 | +42,18 | |
| 6,2500 | +24,75 | |
| 0,9600 | +18,93 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 114,60 | -13,61 | |
| 23,700 | -19,52 | |
| 28,60 | -24,06 | |
| 1,3500 | -25,62 | |
| 0,7800 | -29,73 |
Beitrag zu dieser Diskussion schreiben
FeedbackValeant Pharmaceuticals International Reaches Analyst Target Price
http://www.nasdaq.com/article/valeant-pharmaceuticals-intern… What’s the Next Stop for Valeant Pharmaceuticals Intl Inc.?
https://www.fool.ca/2017/06/27/whats-the-next-stop-for-valea…
Bin erstmal kurzfristig raus, mal sehen ob das clever war 
B + L places focus on innovation in pharma, surgical, vision care
http://ophthalmologytimes.modernmedicine.com/ophthalmologyti…Hatte wir den schon?
Das geht so in die Richtung Produktlinie zum VK an Zeiss?
Are Options Traders Betting on a Big Move in Valeant Pharmaceuticals (VRX) Stock?
https://www.zacks.com/stock/news/265613/are-options-traders-… Trading Spotlight
Im Bashen sind die Amis genauso aktiv, wie im Pushen...
Nachdem die Brüder von Put´s auf Call´s umgesattelt haben machen sie halt anders herum Wind.
Nachdem die Brüder von Put´s auf Call´s umgesattelt haben machen sie halt anders herum Wind.
Ziemlich viel Optimismus bei Stocktwits...
Antwort auf Beitrag Nr.: 55.212.740 von marty44 am 27.06.17 11:00:59wie hoch sind die leerverkauften Aktien? Wer hat einen Link?
https://amigobulls.com/articles/2017-06-27-advanced-micro-de…
...
Short interest in Valeant stock declines sharply.
Short interest in Valeant stock fell sharply towards mid June. As of 15 June, short interest in Valeant fell to 44.8 million shares, from just over 50.4 million shares as of May end, representing a 11% decline in short interest. Seemingly short covering might have had a role to play in the recent rally in VRX stock. While Valeant's 17% YTD gains don't come across as outlandish, its recent gains do catch your attention. VRX shares have shot up by close to 59% in the last three months, of which over 33% of the gains have come in the last 1 month. This coincides with a near 7% reduction in short interest in the preceding cycle, and a 11% fall as of 15 June.
Leaving aside the last two reporting cycles, though, short interest in the stock has risen consistently, with only a few patches of declines and short covering. About a month ago, short interest in VRX stood at over 54 million shares, representing a doubling of short interest from the levels seen in September and October last year. As things stand, days to cover is still high at just under 3 days, implying that short covering could fuel another rally if the stock sees a reasonable upward movement. From a technical standpoint, Valeant's stock price has risen above its 200 day Simple Moving Average (SMA), after breaking out above its 20 day SMA, 50 day and 100 day SMAs earlier this month. The stock is in a strong uptrend. However, it has now entered overbought territory, with the stock price touching the upper Bollinger Band, and the Relative Strength Index (RSI) well past 70. A correction at this point seems like a reasonable possibility.
Welche Erkenntnisse...
...
Short interest in Valeant stock declines sharply.
Short interest in Valeant stock fell sharply towards mid June. As of 15 June, short interest in Valeant fell to 44.8 million shares, from just over 50.4 million shares as of May end, representing a 11% decline in short interest. Seemingly short covering might have had a role to play in the recent rally in VRX stock. While Valeant's 17% YTD gains don't come across as outlandish, its recent gains do catch your attention. VRX shares have shot up by close to 59% in the last three months, of which over 33% of the gains have come in the last 1 month. This coincides with a near 7% reduction in short interest in the preceding cycle, and a 11% fall as of 15 June.
Leaving aside the last two reporting cycles, though, short interest in the stock has risen consistently, with only a few patches of declines and short covering. About a month ago, short interest in VRX stood at over 54 million shares, representing a doubling of short interest from the levels seen in September and October last year. As things stand, days to cover is still high at just under 3 days, implying that short covering could fuel another rally if the stock sees a reasonable upward movement. From a technical standpoint, Valeant's stock price has risen above its 200 day Simple Moving Average (SMA), after breaking out above its 20 day SMA, 50 day and 100 day SMAs earlier this month. The stock is in a strong uptrend. However, it has now entered overbought territory, with the stock price touching the upper Bollinger Band, and the Relative Strength Index (RSI) well past 70. A correction at this point seems like a reasonable possibility.
Welche Erkenntnisse...
Durchsuchen
Bausch Health ehemals VALEANT PHARMA Allergan-Übernahme beflügelt
